CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-NK 细胞疗法治疗恶性肿瘤的临床前与临床研究
英文原题：Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
查看英文原题
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法作为一种特异性免疫疗法，近几十年的发展是血液系统恶性肿瘤治疗领域的重大突破。然而，从患者体内采集正常T细胞的困难以及CAR-T 细胞制备的时间成本限制了CAR-T 细胞疗法的应用。此外，通用型CAR-T 细胞疗法相关临床试验的终止使进一步研究更加困难。自然杀伤（NK）细胞近年来受到广泛关注。嵌合抗原受体NK（CAR-NK）细胞疗法因其不易引起移植物抗宿主病（GVHD），成为治疗恶性肿瘤的一种有前景的策略。在本综述中，我们将讨论CAR-NK细胞疗法的进展与成就。
展开英文摘要原文
The development of chimeric antigen receptor T (CAR-T) cell therapy, a specific type of immunotherapy, in recent decades was a fantastic breakthrough for the treatment of hematological malignancies.
However, difficulties in collecting normal T cells from patients and the time cost of manufacturing CAR-T cells have limited the application of CAR-T-cell therapy.
In addition, the termination of related clinical trials on universal CAR-T cell therapy has made further research more difficult. Natural killer (NK) cells have drawn great attention in recent years. Chimeric antigen receptor-NK (CAR-NK) cell therapy is a promising strategy in the treatment of malignant tumors because of its lack of potential for causing graft-versus-host disease (GVHD). In this review, we will address the advances in and achievements of CAR-NK cell therapy.
论文信息
- 作者
- Li H、Song W、Li Z、Zhang M
- 单位
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36353643 · DOI 10.3389/fimmu.2022.992232
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →